Drug Prices Set To Rise As Centre Weighs Minimum Import Prices For Key Ingredients

India is evaluating MIP for select active pharmaceutical ingredients (APIs) and intermediates to curb import dependence, particularly on China. Officials say the proposal aligns with broader efforts since the PLI scheme to strengthen domestic manufacturing and resilience in essential inputs. The policy discussion has intensified after supply chain vulnerabilities exposed pricing and availability risks for critical drugs.

Pharma manufacturers and industry bodies caution that imposing MIP on APIs and finished formulations would lift input costs across the value chain, translating into higher retail prices for patients. Concerns are most acute among MSMEs, which rely on cost-competitive imports and may struggle to absorb abrupt price floors without transitional support or phased implementation.

Reports indicate government-procured medicines—especially amoxicillin-based products—could see meaningful price increases if MIP is applied. Some analyses flag potential spikes of up to double-digit percentages, with MSME-heavy segments bearing the brunt. The broader context includes recent policy recalibrations around import standards in other sectors, underscoring the balance between safeguarding domestic capability and ensuring affordable access.

Key highlights from the policy discussion include  

• Centre examining MIP for Penicillin-G, 6-APA, and amoxicillin to reduce import reliance.  
• Industry warns MIP could raise API and finished formulation costs, leading to higher drug prices.  
• MSMEs fear margin compression, potential disruption, and employment impacts without phased safeguards.  
• PLIs and domestic capacity-building initiatives frame the push for strategic self-reliance in inputs.  
• Government procurement budgets for antibiotics may face stress if prices rise post-MIP.

The outcome of consultations will determine whether MIP is narrowly targeted, phased, or paired with support measures to mitigate patient impact and safeguard smaller manufacturers. Policymakers face a delicate trade-off: securing domestic resilience without compromising affordability and access to essential medicines.

Sources: Moneycontrol, The Economic Times, Free Press Journal, Times Of India